Alpha-1 Protease Inhibitor Deficiency Epidemiology Forecast 2026-2035

Alpha-1 protease inhibitor (A1PI) deficiency is a hereditary disorder caused by SERPINA1 gene mutations that reduce functional AAT levels below the critical protective threshold of 11 µmol/L, allowing unchecked neutrophil elastase to destroy lung tissue and cause early-onset emphysema, COPD, and progressive liver disease. According to Rare Disease Advisor, AATD affects an estimated 3.4 million individuals with clinically significant disease worldwide, with approximately 117 million carriers globally carrying at least one deficiency allele. As per the Alpha-1 protease inhibitor (A1PI) deficiency epidemiology forecast, growing clinical awareness, expanding augmentation therapy access, and a breakthrough pipeline of gene-editing and RNA-based therapeutics are expected to progressively increase the diagnosed and treated patient pool.

Alpha-1 Protease Inhibitor Deficiency Epidemiology Forecast Report Coverage

The analyst's “Alpha-1 Protease Inhibitor Deficiency Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of alpha-1 protease inhibitor deficiency. It projects the future incidence and prevalence rates of alpha-1 protease inhibitor deficiency cases across various populations. The study covers age, gender, and type as major determinants of the alpha-1 protease inhibitor deficiency population. The report highlights patterns in the prevalence of alpha-1 protease inhibitor deficiency over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of alpha-1 protease inhibitor deficiency in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Alpha-1 Protease Inhibitor Deficiency Understanding: Disease Overview

Alpha-1 protease inhibitor deficiency (AATD) is a hereditary autosomal codominant disorder caused by mutations in the SERPINA1 gene, resulting in critically low levels of alpha-1 antitrypsin (AAT) in the blood and lungs. AAT normally protects lung tissue from neutrophil elastases; without adequate levels, unchecked enzyme activity destroys alveolar tissue, causing early-onset emphysema and COPD. Separately, misfolded AAT protein accumulates in the liver, causing progressive liver disease, including cirrhosis and hepatocellular carcinoma.

Alpha-1 Protease Inhibitor Deficiency Epidemiology Perspective

The alpha-1 protease inhibitor deficiency epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The analyst provides both current and predicted trends for the alpha-1 protease inhibitor deficiency epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for alpha-1 protease inhibitor deficiency and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to Marcelle Meseeha, et al., 2024, individuals with AATD typically experience the first signs of lung disease, between the ages of 20 and 50.
• A study by Staffan Wahlin, et al., 2025, covering 2,286 diagnosed AATD patients between 2002 and 2020, found that the median age at diagnosis was 51 years, with 44% having a pulmonary disease diagnosis at baseline.
• As per Ersöz et al. (EARCO Registry, 2025), among 1,283 AATD patients, 49.3% were women, with females showing lower rates of COPD (41% vs. 57%) and liver disease (11% vs. 20%) but a higher prevalence of bronchiectasis compared to males.
• According to Staffan Wahlin et al., 2025, Alpha-1 protease inhibitor deficiency had an incidence rate of 1.83 per 100,000 person-years and a prevalence of 21.04 per 100,000 persons at the end of 2020, with mortality 3.55 times higher than in the general population, indicating a significant disease burden.
• According to Staffan Wahlin et al., 2025, the condition showed elevated risks of liver, lung, and cardiovascular death with hazard ratios of 22.95, 12.09, and 1.90 respectively, along with a 10-year cumulative incidence of 1.69 percent for liver transplantation and 4.14 percent for lung transplantation.

Country-wise Alpha-1 Protease Inhibitor Deficiency Epidemiology

The alpha-1 protease inhibitor deficiency epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Alpha-1 antitrypsin deficiency (AATD) burden varies across the 8 major markets based on genetic population structure, clinician awareness, testing infrastructure, and access to augmentation therapy. According to the Rare Disease Advisor, the United States carries the highest diagnosed patient share, with an estimated 70,000 to 100,000 severely deficient PiZZ individuals nationally, yet fewer than 10% have received a confirmed diagnosis. The Alpha-1 Foundation maintains key patient registries supporting diagnostic and research infrastructure. As per Kuen-Cheh Yang et al., 2023, in Europe, Northern European nations carry the highest PiZZ gene frequencies globally, with Germany maintaining a national AATD registry and a German Sickness Fund database study confirming rising diagnosed prevalence from 13.3 to 30.1 per 100,000 between 2013 and 2019.

Alpha-1 Protease Inhibitor Deficiency: Treatment Overview

No curative therapy currently exists for alpha-1 protease inhibitor deficiency (AATD). The standard of care is intravenous augmentation therapy using purified, plasma-derived alpha-1 antitrypsin (AAT), first FDA-approved in 1987 (PMC). Administered weekly, it raises serum AAT levels above the protective threshold of 11 µmol/L, helping slow emphysema progression. Five plasma-derived products are FDA-approved, while no approved therapy exists for AATD-related liver disease beyond transplantation. An active pipeline includes gene therapies, RNA interference agents, neutrophil elastase inhibitors, and small-molecule correctors, although none have yet received regulatory approval.

Key Questions Answered

• What are the key findings of alpha-1 protease inhibitor deficiency epidemiology in the 8 major markets?
• What will be the total number of patients with alpha-1 protease inhibitor deficiency across the 8 major markets during the forecast period?
• What was the country-wise alpha-1 protease inhibitor deficiency epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of alpha-1 protease inhibitor deficiency patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of alpha-1 protease inhibitor deficiency during the forecast period of 2026-2035?
• What are the currently available treatments for alpha-1 protease inhibitor deficiency?
• What are the disease risks, signs, symptoms, and unmet needs of alpha-1 protease inhibitor deficiency?

Scope of the Alpha-1 Protease Inhibitor Deficiency Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of Alpha-1 Protease Inhibitor Deficiency based on several factors.
• Alpha-1 Protease Inhibitor Deficiency Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The alpha-1 protease inhibitor deficiency report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.